PHVS
$26.92
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases.
Recent News
Assessing Pharvaris (PHVS) Valuation After Recent Share Price Volatility And DCF Upside Gap
Recent price performance and trigger context Pharvaris (PHVS) has recently drawn investor attention after shares closed at $25.09, with the stock showing a negative 1 day move, a small decline over the past week, and gains over the past month and past 3 months. See our latest analysis for Pharvaris. Looking beyond the recent pullback, Pharvaris has a 30 day share price return of 4.15%, a 90 day share price return of 18.80%, and a 1 year total shareholder return of 36.66%. This suggests...
What Does Wall Street Think About Pharvaris N.V. (PHVS)?
Pharvaris N.V. (NASDAQ:PHVS) is one of the best small cap stocks to buy with huge upside potential. Morgan Stanley analyst Maxwell Skor reiterated a Buy rating on Pharvaris N.V. (NASDAQ:PHVS) on December 15, setting a $41 price target. Pharvaris N.V. (NASDAQ:PHVS) also received a rating update from Oppenheimer on December 4, with the company reaffirming […]
This Biotech Fund Just Made a $22 Million Bet on Pharvaris Stock — Is It a Buy?
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
PHVS shares jump as deucrictibant delivers rapid symptom relief in RAPIDe-3, boosting momentum toward a planned 2026 regulatory filing.
Pharvaris (PHVS) Is Up 5.9% After Phase 3 RAPIDe-3 Win - Has The Bull Case Changed?
In early December 2025, Pharvaris reported positive topline results from its RAPIDe-3 pivotal Phase 3 trial, showing that oral deucrictibant immediate-release capsules met all primary and secondary endpoints for on-demand treatment of hereditary angioedema attacks and will anchor marketing applications planned to start in the first half of 2026. An important angle for investors is that, if the ongoing CHAPTER-3 Phase 3 trial is successful, deucrictibant could become the first oral therapy...